1. HBW Insight

Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium

Consolidated Advertising Complaints Continue, ChromaDex Appeals Patent-Infringement Loss

 
• By Eileen Francis and Malcolm Spicer

California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.

• Source: Alamy

Litigation concerning advertising and patents between nicotinamide riboside supplement firms ChromaDex Corp. and Elysium Health Inc. continue after a California federal court jury renders a split decision on ChromaDex’ complaint that Elysium didn’t pay for supplies it provided.

The jury in the US District Court for Central California found both parties breached contracts: Elysium failed to pay for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

More from HBW Insight

Kenvue Report: Personal Care Is ‘Not A Luxury’, It Is Now A ‘Cornerstone Of Health’

 
• By David Ridley

“Today’s consumers, especially younger generations, are redefining personal care as preventive care,” argues Kenvue on the basis of its latest research into global consumer trends.

California Package Producers Subject To EPR: Deadline For Reporting Materials Is Nov. 15

 
• By Eileen Francis

Circular Action Alliance, the Producer Responsibility Organization managing California’s EPR law, is urging single-use packaging producers subject to the law to register ahead of a November 15 deadline for reporting materials.

Get To Know: Desert Harvest Targets Bacteria Causing Gap In Urinary Tract Health

 
• By Malcolm Spicer

Launching Heather’s UTI Defense, firm partners with Oxford University in clinical trial comparing its supplement head-to-head with D-mannose, most commonly available dietary ingredient for UTI prevention